1. Home
  2. CISS vs SBFM Comparison

CISS vs SBFM Comparison

Compare CISS & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3is Inc.

CISS

C3is Inc.

N/A

Current Price

$1.16

Market Cap

2.7M

ML Signal

N/A

Logo Sunshine Biopharma Inc.

SBFM

Sunshine Biopharma Inc.

N/A

Current Price

$2.33

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CISS
SBFM
Founded
2022
2006
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
2.2M
IPO Year
2022
2008

Fundamental Metrics

Financial Performance
Metric
CISS
SBFM
Price
$1.16
$2.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 371.3K
292.1K
Earning Date
11-18-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $36,305,891.00
Revenue This Year
N/A
$1.23
Revenue Next Year
N/A
$22.44
P/E Ratio
$0.82
★ N/A
Revenue Growth
N/A
★ 4.11
52 Week Low
$0.06
$0.13
52 Week High
$6.06
$15.00

Technical Indicators

Market Signals
Indicator
CISS
SBFM
Relative Strength Index (RSI) 53.06 54.36
Support Level $0.26 $2.01
Resistance Level $1.76 $3.05
Average True Range (ATR) 0.26 0.18
MACD 0.04 -0.10
Stochastic Oscillator 42.27 0.02

Price Performance

Historical Comparison
CISS
SBFM

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including national and private industrial users, commodity producers, and traders. The company owns and operates a fleet of two dry bulk carriers that transport bulk commodities such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.

About SBFM Sunshine Biopharma Inc.

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

Share on Social Networks: